Trade fight moves into software

A three-judge panel in New York spent Friday asking why President Donald Trump could slap a 10% tariff on nearly everything entering the United States just four days after the Supreme Court knocked out most of his earlier tariffs. The tariff took effect on February 24, and 24 mostly Democratic-led states plus two small businesses want the Court of International Trade to block it. (reuters.com) The judges did not rule on April 10, but Reuters reported they sounded skeptical that the administration had found a lawful workaround after the Supreme Court’s February 20 decision. That leaves importers in the same position as a store owner who does not know whether next month’s rent will be the old number or a new one set by a court. (reuters.com) A tariff is a tax paid when a product crosses the border, and companies usually build that tax into the final price they charge wholesalers, pharmacies, hospitals, or shoppers. A 10% tariff can often be absorbed for a while; a tariff that appears, disappears, and then reappears is harder because every contract, invoice, and forecast has to be recalculated. (reuters.com) That legal uncertainty collided this month with a separate White House move aimed at patented medicines. On April 2, Trump issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing a 100% tariff on patented pharmaceutical products and ingredients, with the new duty starting in 120 days for larger companies and 180 days for smaller ones. (whitehouse.gov) Section 232 is the national-security part of trade law, and the White House says imported patented drugs qualify because only 15% of patented active pharmaceutical ingredients by volume are made domestically for the United States market. The proclamation also carves out a United Kingdom exception that starts at 10% and can fall to zero if required by the trade deal with Britain. (whitehouse.gov) RSM US said the 100% pharmaceutical tariff applies to products with valid, unexpired United States patents that appear in the Food and Drug Administration’s Orange Book or Purple Book, which are the government’s lists for approved small-molecule drugs and biologic medicines. RSM also said the rollout is phased, which means companies have a short window to decide whether to import early, shift suppliers, or renegotiate contracts before the higher duty lands. (realeconomy.rsmus.com) That is where the story moves into software. A manufacturer importing a cancer drug from Ireland, a filler ingredient from India, and packaging from Mexico now needs a system that can tell finance teams the landed cost of each shipment after freight, insurance, customs fees, and whichever tariff rate survives court review. (realeconomy.rsmus.com) “Landed cost” is the all-in price of getting a product onto a shelf, like adding the menu price, delivery fee, and service charge before deciding whether takeout is still worth it. If the 10% global tariff is struck down but the 100% patented-drug tariff stays, the answer changes by product, by patent status, and by country of origin. (reuters.com) (whitehouse.gov) The next software problem is supplier substitution, which means finding a different approved source before a shipment becomes uneconomic or unavailable. That is harder in pharmaceuticals than in apparel because a drugmaker cannot swap a patented ingredient the way a sneaker company swaps one zipper vendor for another. (realeconomy.rsmus.com) Independent pharmacies are already describing the pressure at the far end of that chain. A Virginia report from 13News Now said imported prescription drug prices could double under the new tariffs, while pharmacy reimbursements from insurers may not rise fast enough to cover the new acquisition cost. (13newsnow.com) So the immediate fight is in court, but the day-to-day scramble is in enterprise systems. Until judges decide whether the February 24 global tariff stands and companies learn how aggressively the April 2 drug tariffs will be enforced, the winners are likely to be the firms whose software can reprice a shipment, flag an exposed supplier, and reroute an order before the container reaches the port. (reuters.com) (whitehouse.gov)